.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
AstraZeneca
Johnson and Johnson
Cipla
Colorcon
Novartis
Boehringer Ingelheim
Healthtrust
Accenture
Deloitte

Generated: December 18, 2017

DrugPatentWatch Database Preview

Pegaptanib sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for pegaptanib sodium and what is the scope of pegaptanib sodium freedom to operate?

Pegaptanib sodium
is the generic ingredient in one branded drug marketed by Valeant Pharms Llc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegaptanib sodium has three hundred and eighty-two patent family members in thirty-six countries and ten supplementary protection certificates in nine countries.

One supplier is listed for this compound.

Summary for pegaptanib sodium

US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 2,433
Drug Prices:see low prices
DailyMed Link:pegaptanib sodium at DailyMed

Pharmacology for pegaptanib sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pegaptanib sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms LlcMACUGENpegaptanib sodiumINJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pegaptanib sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,874,557 Nucleic acid ligand inhibitors to DNA polymerases► Subscribe
6,177,557 High affinity ligands of basic fibroblast growth factor and thrombin► Subscribe
6,713,616 High affinity TGF.beta. nucleic acid ligands and inhibitors► Subscribe
5,731,144 High affinity TGF.beta. nucleic acid ligands► Subscribe
5,639,868 High-affinity RNA ligands for basic fibroblast growth factor► Subscribe
6,114,120 Systematic evolution of ligands by exponential enrichment: tissue selex► Subscribe
5,726,017 High affinity HIV-1 gag nucleic acid ligands► Subscribe
5,731,424 High affinity TGF.beta. nucleic acid ligands and inhibitors► Subscribe
5,756,287 High affinity HIV integrase inhibitors► Subscribe
5,496,938 Nucleic acid ligands to HIV-RT and HIV-1 rev► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pegaptanib sodium

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0109390► Subscribe
Australia3149595► Subscribe
Israel129497► Subscribe
Canada2209665► Subscribe
Australia2601697► Subscribe
Denmark2080813► Subscribe
China1589908► Subscribe
European Patent Office1042348► Subscribe
Ukraine75578► Subscribe
European Patent Office1032708► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PEGAPTANIB SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/021United Kingdom► SubscribePRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
2006004Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
2006 00021Denmark► Subscribe
20/2006Austria► SubscribePRODUCT NAME: PEGAPTANIB UND SALZE DAVON
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C024/2006Ireland► SubscribeSPC024/2006:, EXPIRES: 20210130
0957929/01Switzerland► SubscribePRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
252Luxembourg► Subscribe91252, EXPIRES: 20210131
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Fuji
US Army
Moodys
McKinsey
Cantor Fitzgerald
Fish and Richardson
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot